Menu
Back to Journals » OncoTargets and Therapy » Volume 15
Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
Authors Pérez-Cárdenas E , Taja-Chayeb L , Trejo-Becerril C, Chanona-Vilchis J, Chávez-Blanco A , Domínguez-Gómez G, Langley E , García-Carrancá A , Dueñas-González A
Received 15 July 2022
Accepted for publication 15 July 2022
Published 4 August 2022 Volume 2022:15 Pages 845—846
Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, et al. Onco Targets Ther. 2018;11:8823–8833.
The authors have advised that an error during the preparation of the slide images for Figure 2C, on page 8827, led to the inadvertent duplication of features on the HV slide. All the original data was retained and the correct image for the HV treated chamber was used as a replacement. The correct Figure 2 is shown in Download Article.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.